Edition:
United States

Emergent BioSolutions Inc (EBS)

EBS on New York Consolidated

35.49USD
17 Aug 2017
Change (% chg)

-- (--)
Prev Close
$35.49
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
303,084
52-wk High
$36.95
52-wk Low
$24.47

Select another date:

Thu, Aug 3 2017

BRIEF-Emergent Biosolutions Q2 earnings per share $0.11

* Emergent Biosolutions reports second quarter and six months 2017 financial results; reaffirms calendar year 2017 guidance

BRIEF-Emergent Biosolutions awarded $23 mln to develop novel multi-drug auto-injector for U.S. Department Of Defense

* Emergent Biosolutions awarded $23 million to develop novel multi-drug auto-injector for U.S. Department of defense Source text for Eikon: Further company coverage:

BRIEF-Emergent Biosolutions Inc - ‍announced a licensing agreement with Valneva SE for global exclusive rights to Valneva's zika vaccine technology, ZIKV​

* Emergent Biosolutions Inc - ‍announced a licensing agreement with Valneva SE for global exclusive rights to Valneva's zika vaccine technology, ZIKV​

BRIEF-Emergent Biosolutions to acquire Raxibacumab from GSK

* Emergent Biosolutions to acquire Raxibacumab, an FDA-approved Anthrax monoclonal antibody, from GSK

BRIEF-Emergent Biosolutions updates terms of termination of agreement related to acquisition of Sanofi's acam2000 business

* Emergent Biosolutions updates on terms of any termination of agreement related to acquisition of acam2000 business from Sanofi

BRIEF-Emergent BioSolutions to acquire ACAM2000 business from Sanofi

* Emergent biosolutions to acquire acam2000® business from sanofi

BRIEF-Emergent Biosolutions reports Q1 revenue $116.9 million

* Emergent Biosolutions reports first quarter 2017 financial results; reaffirms 2017 guidance

BRIEF-Emergent Biosolutions signs $53 mln modification to Barda contract for manufacture of botulism antitoxin

* Emergent Biosolutions signs $53 million modification to Barda contract for the manufacture of botulism antitoxin

BRIEF-Emergent Biosolutions awarded $100 mln BARDA contract

* Emergent Biosolutions awarded $100 million BARDA contract for Biothrax deliveries to the strategic national stockpile

BRIEF-Emergent Biosolutions reports Q4 EPS $0.67

* Fy2017 earnings per share view $2.08, revenue view $543.1 million -- Thomson Reuters I/B/E/S

Select another date: